New developments in psoriasis treatment

July 10, 2014 3:38 AM

33 0

A new drug to combat psoriasis has been shown to be effective in two phase III clinical trials. The drug, secukinumab, is a fully human anti-interleukin-17A monoclonal antibody, a key cytokine (messenger protein) involved in the development of plaque psoriasis, and is found in high concentrations in psoriasis skin plaques.

The results of the studies are the first Phase III data for an IL-17A inhibitor to be published online July 9 in the New England Journal of Medicine and were part of the data submitted to the FDA, with action expected early next year.

Read more

To category page